# Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

> **NCT03952832** · PHASE2 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Smoldering Plasma Cell Myeloma

## Interventions

- **DRUG:** Leflunomide
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03952832
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-11
- **Primary completion:** 2021-06-11
- **Final completion:** 2021-06-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Budget issues
- **Last updated:** 2019-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952832, "Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03952832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*